non-small cell lung cancer

Research Reports
Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer
12/15/2021
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed...
12/15/2021
Journal of Clinical Pathways
Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival
Research Reports
Treatment Pathways for First-Line Metastatic Non-Small Cell Lung Cancer: Cost and Survival
10/21/2020
Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...
Abstract: Value Pathways powered by NCCN™ provides oncologists with a list of clinically proven treatment options that support the delivery of high-quality, cost-effective cancer care. We evaluated the economic and...
...
10/21/2020
Journal of Clinical Pathways
Research Reports
Use of Biomarker Testing in Lung Cancer Among Puerto Rico and Florida Physicians: Results of a Comparative Study
10/18/2019
Abstract: Biomarker-driven therapies are the gold standard of treatment in lung cancer. Recent studies suggest a higher prevalence of specific targetable biomarkers among Hispanic/Latinos (H/L) than non-Hispanic...
Abstract: Biomarker-driven therapies are the gold standard of treatment in lung cancer. Recent studies suggest a higher prevalence of specific targetable biomarkers among Hispanic/Latinos (H/L) than non-Hispanic...
...
10/18/2019
Journal of Clinical Pathways
Research in Review
Time to Surgery After NCRT Affects NSCLC Survival
10/07/2016
JCP Editors
Patients with stage IIIA non-small cell lung cancer (NSCLC) who undergo surgery later than 6 weeks after neoadjuvant chemoradiation (NCRT) may experience significantly lower overall survival, according to results...
Patients with stage IIIA non-small cell lung cancer (NSCLC) who undergo surgery later than 6 weeks after neoadjuvant chemoradiation (NCRT) may experience significantly lower overall survival, according to results...
...
10/07/2016
Journal of Clinical Pathways
Department
PD-L1 Tests for NSCLC Differ in Effectiveness
09/28/2016
JCP Editors
A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...
A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient...
A...
09/28/2016
Journal of Clinical Pathways
Research in Review
PD-1 Inhibitor-Related Pneumonitis Most Common in NSCLC
09/23/2016
JCP Editors
Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...
Pneumonitis is more likely to emerge in patients treated with Programmed cell death 1 (PD-1) inhibitors for non-small cell lung cancer (NSCLC) or renal cell carcinoma versus those being treated for melanoma, a new...
...
09/23/2016
Journal of Clinical Pathways
Research in Review
No Difference in 5-Year Survival With Lung Cancer Staging Strategies
09/21/2016
JCP Editors
New data from a post-hoc analysis of the Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial found no survival difference at 5 years with endosonography or mediastinoscopy...
New data from a post-hoc analysis of the Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial found no survival difference at 5 years with endosonography or mediastinoscopy...
New...
09/21/2016
Journal of Clinical Pathways
Research in Review
Dose Adjustment Reduces AEs Without Impacting Efficacy in NSCLC
09/14/2016
JCP Editors
Tolerability-guided dose adjustment is an effective measure to reduce afatinib (Giotrif)-related adverse events (AEs) without affecting therapeutic efficacy in patients with non–small cell lung cancer (NSCLC),...
Tolerability-guided dose adjustment is an effective measure to reduce afatinib (Giotrif)-related adverse events (AEs) without affecting therapeutic efficacy in patients with non–small cell lung cancer (NSCLC),...
...
09/14/2016
Journal of Clinical Pathways
Research in Review
Little Survival Benefit from WBRT in NSCLC Patients With Brain Metastasis
09/08/2016
JCP Editors
Patients with non-small cell lung cancer and brain metastasis can be spared whole brain radiotherapy (WBRT), as it does little or has no effect on survival and quality of life, according to a study published in The...
Patients with non-small cell lung cancer and brain metastasis can be spared whole brain radiotherapy (WBRT), as it does little or has no effect on survival and quality of life, according to a study published in The...
...
09/08/2016
Journal of Clinical Pathways
Quiz
Friday Morning Quiz – Week of August 15-21
08/18/2016
JCP Editors
A recent study of non-small cell lung cancer found that those with epidermal growth factor receptor (EGFR)-positive disease were at an increased likelihood of developing leptomeningeal metastases (LM), but that...
A recent study of non-small cell lung cancer found that those with epidermal growth factor receptor (EGFR)-positive disease were at an increased likelihood of developing leptomeningeal metastases (LM), but that...
A...
08/18/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use